Newsletter Subject

Drug for Rare Form of ALS Earns FDA Nod

From

medpagetoday.com

Email Address

daily.headlines@broadcaster3.medpagetoday.com

Sent On

Tue, Apr 25, 2023 10:54 PM

Email Preheader Text

Daily Headlines Tuesday, April 25, 2023 Today's Top Stories for {NAME} THE BREAK ROOM CME SPOTLIGHT

[MEDPAGE TODAY]( Daily Headlines Tuesday, April 25, 2023 Today's Top Stories for {NAME} [NEUROLOGY]( [Drug for Rare Form of ALS Earns FDA Nod]( [SPECIAL REPORTS]( [Here Are This Year's Top Graduate Nursing Programs]( [PRACTICE MANAGEMENT]( [Are Physician-Owned Hospitals Good for Healthcare?]( THE BREAK ROOM [Wordectomy: Guess Today’s Medical Condition]( CME SPOTLIGHT [New and Emerging Immunotherapeutic Approaches to Advanced Melanoma]( [MEETING COVERAGE]( [Sigma-1 Selective Drug Disappoints in Huntington's]( [OPINION]( [How Could I Possibly Know What Was 'Best' for My Patient?]( THE BREAK ROOM [Play Today’s Wordosis]( ADVERTISEMENT [MEETING COVERAGE]( [Novel MS Drug Good as Gold in Phase II Study]( CME SPOTLIGHT [Living with HR+/HER2- Breast Cancer: A Point-of-Care Oral Oncolytic Discussion Guide and Toolkit for Patients]( [PODCASTS]( [A Space for Purposeful Rest: Lessons for Clinicians From the Idea of the Sabbath]( [CARDIOLOGY]( [Pre-CABG Statins a Dud; Peak Home BP; Patch vs Multi-Electrode Rhythm Monitors]( [OPINION]( [Atul Gawande on the Importance of Palliative Care]( CME SPOTLIGHT [Applying Evidence-Based Clinical Decision-Making to Real-world Patient Cases to Support Safe, Effective, and Adherent Treatment in TNBC]( [OB/GYN]( [Legal Experts on What's Next for Mifepristone]( [ENDOCRINOLOGY]( [Weight Loss Giants Going Head-to-Head; FDA OKs Omnipod GO; GLP-1 Drugs for Wolfram?]( [MEETING COVERAGE]( [Two Promising Targets in Advanced Cervical Cancer]( CME SPOTLIGHT [Novel Mechanisms and Therapeutic Targets in Relapsed/Refractory Multiple Myeloma]( [PSYCHIATRY]( [Buprenorphine Initiation Rates Stall Despite Policy Efforts to Boost Uptake]( [OPINION]( [Don't Cut Costs You Don't Understand]( [NEUROLOGY]( [Melatonin Gummies May Not Be What They Claim to Be]( CME SPOTLIGHT [Individualizing von Willebrand Disease Treatment Strategies for Patients With Severe and Frequent Bleeds]( [INFECTIOUS DISEASE]( [Myasthenia Gravis Tied to Elevated Risk for Severe COVID]( [ASCO READING ROOM]( [Ann LaCasce, MD, on PET-Adapted Therapy for Hodgkin Lymphoma]( [ONCOLOGY/HEMATOLOGY]( [Perioperative Toripalimab Prolongs EFS in Stage III Lung Cancer]( CME SPOTLIGHT [Evidence-Based Strategies for Integrating CAR T-Cell Therapy Into Non-Hodgkin Lymphoma Care]( [SPECIAL REPORTS]( [Doctors More Neurotic, Less Open Than Patients, Surveys Find]( # Weekly Survey [Background Checks in Healthcare Up to Snuff?]( One [fired hospital administrator's story]( reveals flaws in healthcare's hiring system, which may be particularly vulnerable as facilities face pressure to fill vacancies[VOTE >]( Meeting Coverage Can't get away? MedPage Today brings you extensive coverage of more than 80 meetings in a wide range of specialties. [SEE ALL STORIES >]( Got a news tip? MedPage Today offers several ways to provide information to our journalists securely and confidentially. [LEARN MORE >]( [EVERYDAY HEALTH]( © 2023 MedPage Today, LLC. MedPage Today is among the federally registered trademarks of MedPage Today, LLC, and may not be used by third parties without explicit permission. You have received this email because you have registered to receive emails at www.medpagetoday.com, with the email address: {EMAIL} [Manage Email Preferences]( | [Unsubscribe](lst=NL_Daily_DHE?xid=nl_mpt_DHE_2023-04-25&eun=g1020308d0r) | [Terms of Use]( | [Privacy Policy]( Technical Questions: feedback@medpagetoday.com 114 5th Avenue, 15th Floor New York, NY 10011

Marketing emails from medpagetoday.com

View More
Sent On

08/12/2024

Sent On

08/11/2024

Sent On

07/11/2024

Sent On

07/11/2024

Sent On

06/11/2024

Sent On

04/11/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2025 SimilarMail.